Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder (POLE)
This study has been completed.
Information provided by:
First received: September 2, 2008
Last updated: October 3, 2008
Last verified: September 2008
The purpose of this study is to reassure the clinical study data on atypical antipsychotics effect on quality of life in Korean Bipolar patients.
|Official Title:||A 8-Week, Multicenter, Open-Label, Observational Study of Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder|
Resource links provided by NLM:
Further study details as provided by AstraZeneca:
Primary Outcome Measures:
- The change from the baseline to week 8 in Short Form of the Quality of Life Enjoyment and satisfaction Questionnaire (Q-LES-Q) score
Secondary Outcome Measures:
- The change from the baseline to week 8 in CGI-BP and GAF scale score.
|Study Start Date:||July 2008|
|Primary Completion Date:||September 2008 (Final data collection date for primary outcome measure)|
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00745966
|Korea, Republic of|
|Kyunggi-do, Choonchun-si, Korea, Republic of|
|Dae-gu, Joong-gu, Korea, Republic of|
Sponsors and Collaborators
|Study Director:||Joon-Woo Bahn||Astrazeneca, Korea|